News that a patient may have died from using an ingredient found in an active ingredient in Tecfidera, manufactured and marketed by Biogen, Inc. has riveted the biotech community, after Dutch physicians published a case study last Thursday in The New England Journal of Medicine. BioSpace wants to know what you think could be the fallout.
